🇺🇸 RCUS — Arcus Biosciences, Inc.

Salud Compra fuerte
← Volver

Precio actual

18,91 USD

Máx. histórico

48,47

1806 días

Caída desde máximo

-60,99%

Rango 52 semanas

17,43 – 31,74

Variación hoy

+5,94%

Cierre anterior

17,85

Rango de hoy

18,05 – 18,98

Volumen hoy

1.935.563

Peor caída histórica

-85,83%

23/11/2021 → 04/04/2025

Aún sin recuperar

Volatilidad anualizada ⓘ

75,63%

Información
Nombre completo
Arcus Biosciences, Inc.
Divisa
USD
Mercado
NYSE
Sector
Salud
Industria
Biotechnology
Empleados
601
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
41,00 USD (puede no estar actualizado)
Primera cotización
15/03/2018
Precio actualizado
hace 20 horas
Sobre la empresa

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases; and Bristol-Myers Squibb Company to develop a novel treatment regimen that delivers tumor control in kidney cancer. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
14/07/2025 9,28 9,68 9,17 9,65 +3,43% 5,50% 607.600
11/07/2025 9,38 9,48 9,25 9,33 -2,20% 2,51% 546.000
10/07/2025 9,91 9,97 9,28 9,54 +2,25% 6,97% 688.700
09/07/2025 8,57 9,39 8,57 9,33 +9,76% 9,51% 818.900
08/07/2025 8,24 8,65 8,23 8,50 +3,41% 5,10% 1.432.000
07/07/2025 8,35 8,39 8,03 8,22 -2,95% 4,31% 858.700
03/07/2025 8,60 8,75 8,33 8,47 -1,40% 4,88% 297.200
02/07/2025 8,39 8,81 8,30 8,59 +2,75% 6,08% 710.200
01/07/2025 8,14 8,61 7,92 8,36 +2,70% 8,44% 1.090.400
30/06/2025 8,05 8,41 8,01 8,14 +2,39% 4,97% 1.118.300
27/06/2025 8,48 8,64 7,91 7,95 -6,47% 8,61% 3.749.800
26/06/2025 8,61 8,75 8,48 8,50 -1,39% 3,14% 637.300
25/06/2025 8,75 8,75 8,36 8,62 -1,49% 4,46% 1.278.400
24/06/2025 8,74 8,87 8,48 8,75 +1,39% 4,46% 681.000
23/06/2025 8,60 8,75 8,38 8,63 +0,12% 4,30% 638.900
20/06/2025 8,58 8,74 8,31 8,62 +1,29% 5,01% 1.325.200
18/06/2025 8,72 8,87 8,51 8,51 -2,18% 4,13% 846.900
17/06/2025 9,00 9,18 8,69 8,70 -4,29% 5,44% 864.500
16/06/2025 9,30 9,35 8,92 9,09 -1,62% 4,57% 655.500
13/06/2025 9,13 9,34 8,94 9,24 -1,18% 4,38% 781.400
12/06/2025 9,00 9,49 8,75 9,35 +2,97% 8,19% 2.864.000
11/06/2025 10,08 10,16 9,07 9,08 -9,38% 10,76% 1.802.700
10/06/2025 10,02 10,29 9,91 10,02 +1,73% 3,74% 873.400
09/06/2025 10,29 10,29 9,72 9,85 -1,20% 5,54% 735.100
06/06/2025 9,74 10,11 9,66 9,97 +3,53% 4,58% 843.800
05/06/2025 9,58 9,69 9,29 9,63 +0,31% 4,18% 639.000
04/06/2025 9,95 10,14 9,41 9,60 -4,29% 7,29% 921.800
03/06/2025 9,19 10,68 9,03 10,03 +8,79% 17,95% 1.693.500
02/06/2025 9,16 9,40 8,76 9,22 +3,25% 6,99% 1.482.400
30/05/2025 9,38 9,38 8,55 8,93 -6,10% 8,85% 1.379.600